New Risk • Apr 21
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 15% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Market cap is less than US$100m (CA$19.6m market cap, or US$14.3m). 공시 • Feb 23
DiagnosTear Technologies Inc., Annual General Meeting, Apr 20, 2026 DiagnosTear Technologies Inc., Annual General Meeting, Apr 20, 2026. Location: british columbia, vancouver Canada 공시 • Jan 19
Diagnostear Technologies Inc. Announces Highly Encouraging Interim Results from Its Ongoing Multi-Center Israeli Clinical Study DiagnosTear Technologies Inc. announced highly encouraging interim results from its ongoing multi-center Israeli clinical study supporting the development of its TeaRxTM Red Eye diagnostic platform. TeaRxTM Red Eye is being developed as the first rapid, multi-biomarker, point-of-care diagnostic device designed to differentiate between Adenoviral conjunctivitis, Herpetic keratitis, and Allergic conjunctivitis - three clinically similar but therapeutically distinct causes of red eye that together account for hundreds of millions of clinic visits worldwide each year. The lack of rapid, objective diagnostics for these conditions continues to drive misdiagnosis, inappropriate treatment, and unnecessary antibiotic and antiviral use. The Israeli clinical program was initiated in October 2023 and is being conducted across leading community and hospital sites, including two Leumit Health Services clinics in Tel-Aviv and Jerusalem, one Clalit Health Services clinic in Jerusalem, Kaplan Medical Center in Rehovot, share Zedek Medical Center in Jerusalem, and Soroka Medical Center in Beer-Sheva. The study enrolls patients presenting with suspected infectious or allergic red eye and involves collection of tear fluid samples by conjunctival swabbing.
Each sample is independently characterized using established laboratory reference methods, including qPCR testing for ocular Herpes (HSV-1 and HSV-2), qPCR and the QuickVue® Adenovirus test (QuidelOrtho), for Adenovirus, and quantitative ELISA for total tear IgE (biomarker for ocular allergy), and is tested in parallel using the TeaRxTM Red Eye assay. To date, 130 subjects have been recruited into this study. Among these, 66 samples have been evaluated for adenovirus, 60 for HSV-1/2, and 61 for total tear IgE, meeting protocol criteria for eligibility. Based on these eligible samples, TeaRxTM Red Eye has demonstrated excellent positive and negative agreement rates of 92% and 100% for Adenovirus, 100% and 100% for HSV-1/2, and 73% and 93% for total tear IgE, respectively, when compared to the independent reference methods. These interim results indicate that TeaRxTM Red Eye reliably identifies viral causes of red eye, supporting clearer point-of-care decisions and reducing unnecessary treatments. The Israeli study is expected to be completed by the second quarter of 2026. As previously reported, DiagnosTear has also initiated complementary clinical programs in India, focused on HSV, and in
France, focused on tear IgE for allergic conjunctivitis, both of which are also expected to be completed by the second quarter of 2026. Together, these studies are designed to support regulatory submissions and global commercialization of TeaRxTM Red Eye. 공시 • Nov 19
DiagnosTear Technologies Inc. announced that it has received CAD 0.925 million in funding On November 18, 2025, DiagnosTear Technologies Inc. closed the transaction. The company issued 1,850,000 units at an issue price of CAD 0.50 per unit for gross proceeds of CAD 925,000 in the transaction. Each warrant will be exercisable to purchase one common share for a term of eighteen months from the closing date of the offering, which will be May 18, 2027. No finder's fees were paid in connection with this offering. 공시 • Jun 04
DiagnosTear Technologies Inc. announced that it expects to receive CAD 0.7 million in funding DiagnosTear Technologies Inc. announced a non-brokered private placement of 1,400,000 units at a price of CAD 0.5 per unit for the gross proceeds of CAD 700,000 on June 3, 2025. Each unit will consist of one common share of the company and one common share purchase warrant. Each warrant will be exercisable to purchase one common share at an exercise price of CAD 1.00 for a term of eighteen months from the closing date of the offering. All securities issued in connection with the offering will be subject to a statutory hold period expiring four months and one day after the issuance thereof. New Risk • Apr 19
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: CA$13.5m (US$9.77m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (21% average weekly change). Market cap is less than US$10m (CA$13.5m market cap, or US$9.77m). 공시 • Feb 17
DiagnosTear Technologies Inc., Annual General Meeting, Apr 24, 2025 DiagnosTear Technologies Inc., Annual General Meeting, Apr 24, 2025.